IPO - Kyverna Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-04-15

Corporate Action: Ipo

Type: New

Accession Number: 000095017025054293

Filing Summary: Kyverna Therapeutics, Inc. filed a prospectus under Rule 424(b)(5) for an offering of up to $50,000,000 in common stock. The offering is pursuant to an Open Market Sale Agreement with Jefferies LLC, allowing sales at market prices through or to Jefferies acting as sales agent. The prospectus indicates that Kyverna’s common stock is listed on the Nasdaq Global Select Market under the symbol 'KYTX'. As of March 26, 2025, the stock's closing price was $2.50 per share. The funds raised will be utilized for general corporate purposes, including research and development and working capital. Kyverna is classified as an emerging growth company and smaller reporting company, benefiting from reduced public company reporting requirements. The document details risks involved in investing due to the company’s clinical stage and lack of products on the market, emphasizing the uncertainties related to the offering and market conditions.